Currently conducting Japanese business in the U.S - where the...

Currently conducting Japanese business in the U.S - where the biotech markets seem to be thriving and liquid - well, considerably more than the ASX - that's for sure.

Sitting in a busy cafe along Wall Street two days ago during peak hour, I was astounded to hear two executives, likely to be corporate brokers, discussing a biotech company by the name of "Rhythm" to be listed on the ASX. Chills went up my spine in excitement as I tried to eavesdrop closer. Alas, the cafe was simply too loud and busy to hear much at all.

Saying that, one should really take a close look at the T20 upon listing. I feel there will be some accumulation games to be played initially, but that is probably just the start of the freight train coming through.